

# Like any other drug?

As with any other drug, some vaccines are more useful than others. Some are useful when a large population is vaccinated; others should only be given to persons at particularly high risk. Some are pointless, perhaps because they offer protection against a benign condition; others have harms that are disproportionate to their minimal or uncertain efficacy.

Like any other drug, a vaccine's efficacy is best evaluated in comparative clinical trials. The design of these trials must take into account: the incidence of the infection; its natural history, to determine which endpoints to use, primarily clinical endpoints for a rapidly progressing disease; the existence of persons at increased risk of developing complications, to ensure they are enrolled in sufficient numbers; and the environments in which the populations most concerned live and where the trial is to be conducted.

As with any other drug, the data available for the analysis of a vaccine's adverse effects are often less robust than those available for analysis of its efficacy. It is also essential to look into a vaccine's foreseeable risks, based on its pharmacology: is it a type of vaccine that is well known and has already been used, e.g. based on an inactivated virus or a live attenuated virus? Does it contain adjuvants? Are these adjuvants well known and have they already been used? What long-term harms should be taken into consideration?

When all of these factors are taken into account, a vaccine sometimes clearly represents a therapeutic advance, as is the case for the Ebola vaccine rVSV-Zebov (Ervebo®) (see pp. 33-37 of this issue). The results of its evaluation, based on tangible outcomes for those most at risk, are convincing and justify the risks.

## Prescrire

► Translated from *Rev Prescrire* **December 2020**  
Volume 40 N° 446 • Page 884



## Follow Prescrire International on Facebook and Twitter

Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients.

EDITORIAL